• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioTime touts preclinical results for hydrogel drug-delivery implant

December 4, 2018 By Sarah Faulkner

BioTimeBioTime Inc. (NYSE:BTX) touted today positive preclinical results for its HyStem hydrogel drug-delivery technology, demonstrating that targeted intracerebral delivery of brain-derived neurotrophic factor may alleviate the effects of ischemic brain injury and reduce neuroinflammation.

The study, published in the International Journal of Molecular Sciences, focused on the effects of BDNF on sensorimotor function, infarct volume and neuroinflammation following permanent distal middle cerebral artery occulsion in rats.

The researchers observed that sensorimotor function improved in the rats treated with BioTime’s hydrogel + BDNF, especially six to eight weeks following treatment. The company also reported that infarct volume was reduced in rats treated using the hydrogel drug-delivery implant.

“Results from this study, designed to simulate the clinical needs of human stroke, underscore the ability of our proprietary HyStem delivery technology to target therapy dosing to a specific anatomical site such as to the ischemic core, and minimize dissipation to surrounding tissues,” Francois Binette, SVP & global head of product development at BioTime, said in prepared remarks.

“Brain-derived neurotrophic factor (BDNF) is responsible for regulating neural stem cell differentiation and survival, synapse development, and plays a key role in the neuro-reparative processes that mediate cortical connectivity and promote post-stroke recovery. In this model, utilizing our HyStem delivery platform, BDNF was shown over a three-week period to be continuously released to the surrounding tissue, which could allow for better long-term tissue and functional effects to occur compared to a regular bolus injection,” Binette added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: BioTime Inc.

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS